Advertisement
Advertisement
JANX
Janux Therapeutics, Inc. Common Stock
14.61
USDSponsored
+0.20
+1.39%
May 13, 16:00 UTC -4
Closed
Pre-Market
14.49
-0.12
-0.81%
JANX Earnings Reports
Positive Surprise Ratio
JANX beat 14 of 20 last estimates.
70%
Next Report
Date of Next Report
Aug 05, 2026
Estimate for Q2 26 (Revenue/ EPS)
$12.83M
/-$0.46
Implied change from Q1 26 (Revenue/ EPS)
+243.65%
/+17.95%
Implied change from Q2 25 (Revenue/ EPS)
--
/-16.36%
Janux Therapeutics, Inc. Common Stock earnings per share and revenue
On May 07, 2026, JANX reported earnings of -0.39 USD per share (EPS) for Q1 26, beating the estimate of -0.53 USD, resulting in a 27.36% surprise. Revenue reached 3.73 million, compared to an expected 3.91 million, with a -4.53% difference. The market reacted with a -2.51% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 15 analysts forecast an EPS of -0.46 USD, with revenue projected to reach 12.83 million USD, implying an increase of 17.95% EPS, and increase of 243.65% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
CorMedix Inc.
Report Date
May 14, 2026 For Q1 26
Estimate
$0.37
Actual
$0.43
Surprise
+15.59%
Invivyd, Inc. Common Stock
Report Date
May 14, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.13
Surprise
-73.80%
REGENXBIO Inc.
Report Date
May 14, 2026 For Q1 26
Estimate
-$1.36
Actual
-$1.72
Surprise
-25.94%
Autolus Therapeutics plc - ADR
Report Date
May 14, 2026 For Q1 26
Estimate
-$0.26
Actual
-$0.27
Surprise
-2.94%
Fennec Pharmaceuticals Inc. Common Stock
Report Date
May 14, 2026 For Q1 26
Estimate
$0.00
Actual
$0.01
Surprise
+217.65%
Pelthos Therapeutics Inc.
Report Date
May 14, 2026 For Q1 26
Estimate
-$3.34
Actual
-$3.09
Surprise
+7.55%
Dogwood Therapeutics, Inc. Common Stock
Report Date
May 14, 2026 For Q1 26
Estimate
-$0.26
Actual
-$0.15
Surprise
+42.70%
Tango Therapeutics, Inc.
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.31
Actual
-$0.32
Surprise
-0.13%
Hyperion DeFi, Inc. Common Stock
Report Date
May 14, 2026 For Q1 26
Estimate
$0.74
Actual
-$0.82
Surprise
-210.13%
Bionano Genomics, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.96
Actual
-$0.76
Surprise
+21.57%
FAQ
What were Janux Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Janux Therapeutics, Inc. Common Stock reported EPS of -$0.39, beating estimates by 27.36%, and revenue of $3.73M, -4.53% below expectations.
How did the market react to Janux Therapeutics, Inc. Common Stock's Q1 2026 earnings?
The stock price moved down -2.51%, changed from $14.54 before the earnings release to $14.18 the day after.
When is Janux Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 05, 2026.
What are the forecasts for Janux Therapeutics, Inc. Common Stock's next earnings report?
Based on 15
analysts, Janux Therapeutics, Inc. Common Stock is expected to report EPS of -$0.46 and revenue of $12.83M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement